

## Symproic<sup>®</sup> (naldemedine) – New drug approval

- On March 24, 2017, <u>Shionogi</u> and <u>Purdue Pharma announced</u> the <u>FDA approval</u> of <u>Symproic</u> (<u>naldemedine</u>) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
  - Symproic is a Schedule II controlled substance.
  - The descheduling of Symproic is currently under evaluation by the U.S. Drug Enforcement Agency (DEA) based on a petition by Shionogi.
- Constipation is a commonly reported side effect associated with opioid treatment. The prevalence of OIC in patients with chronic non-cancer pain is estimated to range between 40 50%.
- Symproic is a peripherally-acting opioid receptor antagonist and is structurally related to <u>naltrexone</u>. It acts on tissues such as the gastrointestinal tract to decrease the constipating effects of opioids.
- The safety and efficacy of Symproic were demonstrated in 3 clinical trials that were part of the COMPOSE program enrolling patients with OIC and chronic non-cancer pain. Efficacy was assessed using a responder analysis. A responder was defined as a patient who had at least 3 spontaneous bowel movements (SBMs) per week and a change from baseline of at least 1 SBM per week for at least 9 out of the 12 weeks and 3 out of the last 4 weeks.
  - In study 1, 48% of Symproic-treated patients were responders vs. 35% of placebo patients (treatment difference = 13% [95% CI: 5, 21; p = 0.0020]).
  - In study 2, 53% of Symproic-treated patients were responders vs. 34% of placebo patients (treatment difference = 19% [95% CI: 11, 27; p < 0.0001]).</li>
  - Symproic was also evaluated in a 52 week, placebo-controlled long-term safety trial.
- Symproic is contraindicated in patients with known or suspected gastrointestinal obstruction or at increased risk of recurrent obstruction, and in patients with a history of a hypersensitivity reaction to Symproic.
- Warnings and precautions of Symproic include gastrointestinal perforation and opioid withdrawal.
- The most common adverse reactions (≥ 2%) with Symproic use were abdominal pain, diarrhea, and nausea.
- The recommended starting dose of Symproic is 0.2 mg orally once daily with or without food.
  - Patients receiving opioids for < 4 weeks may be less responsive to Symproic.</li>
  - Symproic should be discontinued if treatment with the opioid pain medication is discontinued.
- Shionogi and Purdue Pharma plan to launch Symproic in mid-summer 2017. Symproic will be available as 0.2 mg film-coated tablets.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.